Increasing radiation therapy and lower survival for human papillomavirus-related oropharynx cancer associated with a shift to community cancer center care

被引:1
|
作者
Trakimas, Danielle R. [1 ]
Mydlarz, Wojtek [1 ]
Mady, Leila J. [1 ]
Koch, Wayne [1 ]
Quon, Harry [1 ,2 ]
London, Nyall R., Jr. [1 ]
Fakhry, Carole [1 ,3 ]
机构
[1] Johns Hopkins Univ Hosp, Dept Otolaryngol Head & Neck Surg, 601 N Caroline St, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ Hosp, Dept Radiat Oncol, Baltimore, MD USA
[3] Johns Hopkins Univ Hosp, Dept Oncol, Baltimore, MD USA
来源
基金
美国国家卫生研究院;
关键词
HIGH-VOLUME FACILITIES; SHORT-TERM OUTCOMES; HOSPITAL VOLUME; HEAD; SURGERY; COST; TRENDS; PREVALENCE; CARCINOMA; IMRT;
D O I
10.1093/jnci/djad238
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Studies have shown lower overall survival for patients with head and neck cancer treated at low-volume or community cancer centers. As the incidence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma steadily rises in the United States, we hypothesized that a greater proportion of patients with HPV-related oropharyngeal squamous cell carcinoma is being treated at community cancer centers, with a shift toward primary nonsurgical treatment.Methods: This cohort study included patients from the US National Cancer Database who received a diagnosis of HPV-related oropharyngeal squamous cell carcinoma from 2010 to 2019 and underwent treatment at a community cancer center or academic cancer center. The proportion of patients with HPV-related oropharyngeal squamous cell carcinoma treated at community cancer centers and receiving primary nonsurgical treatment was analyzed over time. Four-year overall survival was compared between community cancer centers and academic cancer centers.Results: The majority (67.4%) of 20 298 patients were treated at an academic cancer center, yet the proportion of patients treated at community cancer centers increased by 10% from 2010 to 2019 (P < .01 for trend). The proportion of patients undergoing primary nonsurgical treatment increased from 62.1% to 73.7% from 2010 to 2019 (P < .01 for trend), and patients were statistically significantly more likely to undergo nonsurgical treatment at community cancer centers than at academic cancer centers (adjusted odds ratio = 1.20, 95% confidence interval = 1.18 to 1.22). Treatment at community cancer centers was associated with worse survival overall (adjusted hazard ratio = 1.19, 95% confidence interval = 1.09 to 1.31), specifically for patients receiving primary nonsurgical treatment (adjusted hazard ratio = 1.22, 95% confidence interval = 1.11 to 1.34).Conclusions: Treatment of HPV-related oropharyngeal squamous cell carcinoma has recently shifted to community cancer centers, with an increase in the proportion of nonsurgical treatment and worse overall survival at these centers compared with academic cancer centers. Concentration of care for HPV-related oropharyngeal squamous cell carcinoma at academic cancer centers and dedicated head and neck cancer centers may increase access to all available treatment modalities and improve survival.
引用
收藏
页码:1051 / 1062
页数:12
相关论文
共 50 条
  • [1] Lower survival for surgical treatment of human papillomavirus-related oropharynx cancer at community cancer centers
    Trakimas, Danielle R.
    Mydlarz, Wojciech K.
    Mady, Leila J.
    Gourin, Christine G.
    Koch, Wayne
    London Jr, Nyall R.
    Quon, Harry
    Kiess, Ana P.
    Seiwert, Tanguy Y.
    Fakhry, Carole
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024,
  • [2] Hypofractionated radiation therapy alone for human papillomavirus-related oropharyngeal cancer
    Chen, Allen M.
    Harris, Jeremy P.
    Tjoa, Tjoson
    Haidar, Yarah
    Armstrong, William B.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2025, 47 (01): : 235 - 241
  • [3] Distinct biomarker and behavioral profiles of human papillomavirus-related oropharynx cancer patients by age
    Fakhry, Carole
    Waterboer, Tim
    Westra, William H.
    Rooper, Lisa M.
    Windon, Melina
    Troy, Tanya
    Koch, Wayne
    Gourin, Christine G.
    Bender, Noemi
    Yavvari, Siddhartha
    Kiess, Ana P.
    Miles, Brett A.
    Ryan, William R.
    Ha, Patrick K.
    Eisele, David W.
    D'Souza, Gypsyamber
    ORAL ONCOLOGY, 2020, 101
  • [4] Human papillomavirus-related oropharyngeal cancer
    Taberna, M.
    Mena, M.
    Pavon, M. A.
    Alemany, L.
    Gillison, M. L.
    Mesia, R.
    ANNALS OF ONCOLOGY, 2017, 28 (10) : 2386 - 2398
  • [5] Human Papillomavirus-related tumours of the oropharynx display a lower tumour hypoxia signature
    Hanns, Elodie
    Job, Sylvie
    Coliat, Pierre
    Wasylyk, Christine
    Ramolu, Ludivine
    Pencreach, Erwan
    Suarez-Carmona, Meggy
    Herfs, Michael
    Ledrappier, Sonia
    Macabre, Christine
    Abecassis, Joseph
    Wasylyk, Bohdan
    Jung, Alain C.
    ORAL ONCOLOGY, 2015, 51 (09) : 848 - 856
  • [6] Human Papillomavirus Vaccination and Human Papillomavirus-Related Cancer Rates
    Adekanmbi, Victor
    Sokale, Itunu
    Guo, Fangjian
    Ngo, Jessica
    Hoang, Thao N.
    Hsu, Christine D.
    Oluyomi, Abiodun
    Berenson, Abbey B.
    JAMA NETWORK OPEN, 2024, 7 (09)
  • [7] New Strategies in Human Papillomavirus-Related Oropharynx Cancer: Effecting Advances in Treatment for a Growing Epidemic
    Massarelli, Erminia
    Ferrarotto, Renata
    Glisson, Bonnie S.
    CLINICAL CANCER RESEARCH, 2015, 21 (17) : 3821 - 3828
  • [8] Immune Response During Therapy With Cisplatin or Radiation for Human Papillomavirus-Related Head and Neck Cancer
    Spanos, William C.
    Nowicki, Paul
    Lee, Dong Wook
    Hoover, Andrew
    Hostager, Bruce
    Gupta, Anjali
    Anderson, Mary E.
    Lee, John H.
    ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2009, 135 (11) : 1137 - 1146
  • [9] Human Papillomavirus-Related Oropharyngeal Cancer in Women
    Scaffidi, Rose M.
    Gerhardt, Jill
    Eisele, Cheryle
    JOURNAL OF MIDWIFERY & WOMENS HEALTH, 2016, 61 (03) : 380 - 383
  • [10] Human Papillomavirus-Related Cancer Vaccine Strategies
    Cai, Xia
    Xu, Ling
    VACCINES, 2024, 12 (11)